AzaSite + Tobramycin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bacterial Conjunctivitis
Conditions
Bacterial Conjunctivitis
Trial Timeline
Jul 1, 2004 → Oct 1, 2005
NCT ID
NCT00105469About AzaSite + Tobramycin
AzaSite + Tobramycin is a phase 3 stage product being developed by Merck for Bacterial Conjunctivitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00105469. Target conditions include Bacterial Conjunctivitis.
What happened to similar drugs?
18 of 20 similar drugs in Bacterial Conjunctivitis were approved
Approved (18) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00105469 | Phase 3 | Completed |
Competing Products
20 competing products in Bacterial Conjunctivitis